Subscribe to Bilal Sayyed's Posts
Bilal Sayyed represents clients before the Federal Trade Commission (FTC) and Department of Justice (DOJ) in significant merger, civil and criminal antitrust matters. In addition to his representation of clients in antitrust and competition matters, Bilal represents clients before the FTC in consumer protection investigations. Read Bilal Sayyed's full bio.
THE LATEST: Learnings from Merger Remedies Study Underscores FTC’s Heightened Focus on Remedy Packages and Proposed Buyers
By Bilal Sayyed and Gregory E. Heltzer on Feb 22, 2017
Posted In FTC Developments, Mergers & Acquisitions
WHAT HAPPENED: In early February, the FTC released its Merger Remedies Study (the Study), which focused on transactions from 2006-2012 in which the FTC found a competitive problem that did not require a block outright, and allowed the transaction to gain clearance so long as the merging parties agreed to what the FTC determined were appropriate...
President-Elect Trump Has Once-in-a-Century Opportunity to Substantially Revise the FTC’s Law Enforcement and Regulatory Agenda
By Bilal Sayyed on Jan 6, 2017
Posted In FTC Developments, Private Litigation
Bilal Sayyed, a McDermott partner and former official at the Federal Trade Commission, has prepared a thoughtful series of recommendations for actions which the new administration’s FTC might take. His paper considers options which the new administration may take based on prior precedents. Read the full report here.
US and EU Requirements for Pre-Merger Notification of an Acquisition of a Minority Shareholding Interest
By Bilal Sayyed and McDermott Will & Emery on Aug 31, 2016
Posted In DOJ Developments, EC Developments, EU Developments, Joint Ventures/Competitor Collaboration, Mergers & Acquisitions
In May, the Federal Trade Commission (FTC) required Hikma Pharmaceuticals PLC to divest its 23 percent interest in Unimark Remedies, Ltd. and its US marketing rights to a generic drug under manufacture by Unimark as a condition to allowing Hikma to complete its acquisition of Roxane Laboratories. The FTC was concerned that Hikma’s continued holding...
By Raymond A. Jacobsen, Jr., Joel R. Grosberg, Jon B. Dubrow, Bilal Sayyed and McDermott Will & Emery on May 18, 2016
Posted In DOJ Developments, FTC Developments, Mergers & Acquisitions
In the last year, the US antitrust regulators successfully challenged multiple transactions in court and forced companies to abandon several other transactions as a result of threatened enforcement actions. Looking back at the different cases, there are some trends that we see developing in the government’s positioning on mergers, and these should be kept in...